Market Overview:
The global central nervous system (CNS) stimulant drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The CNS stimulant drugs market is segmented on the basis of type, application and region. On the basis of type, the CNS stimulant drugs market is segmented into attention-deficit hyperactivity disorder (ADHD), narcolepsy and others. On the basis of application, the CNS stimulant drugs market is segmented into hospital, research institutes and research institutions, clinic and other applications.
 Stimulant Drugs Industry Outlook.svg)
Product Definition:
Central Nervous System (CNS) Stimulant Drugs are drugs that stimulate the central nervous system. They are used to treat conditions such as narcolepsy, attention deficit hyperactivity disorder (ADHD), and obesity. CNS stimulants can improve focus, energy levels, and motivation. They can also help people lose weight by increasing caloric expenditure. However, CNS stimulants can also cause side effects such as anxiety, insomnia, and cardiovascular problems.
Attention-deficit Hyperactivity Disorder:
Attention-deficit/hyperactivity disorder (ADHD) is a neurochemical imbalance that affects the way the brain reacts to stimuli. It is characterized by symptoms such as inability to pay attention, hyperactivity, and impulsive behavior. According to statistics published in 2013 by the Centers for Disease Control and Prevention (CDC), it was estimated that 4% of children between 2-17 years of age are affected with ADHD.
Narcolepsy:
narcolepsy is a sleep disorder, characterized by uncontrollable sleep attacks. It used to be called the Dutch Disease due to its prevalence in Holland. The disease has an incidence of 1:10,000 and is more common in males (1:4) than females (1:5).
The stimulant drug market for CNS stimulants was valued at USD 7.2 billion in 2015.
Application Insights:
The other application segment includes use in cosmetic industry, as a food additive, and for weight loss. Stimulant drugs are widely used across all major industries including healthcare, cosmetics and food owing to their ability to heighten mental alertness. However, the Food & Drug Administration (FDA) has strict guidelines on the usage of stimulants in food products due to potential side effects associated with them.
The hospital segment accounted for the largest share of CNS stimulant drug market revenue in 2017 due to high prevalence of neurological disorders that require regular medication along with surgery procedures performed at hospitals every day.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of CNS stimulant-associated disorders are some factors responsible for its dominance. According to the data published by National Center for Health Statistics (NCHS), in 2016 about 11.1 million children and 6.7 million adults were diagnosed with attention-deficit/hyperactivity disorder (ADHD). Moreover, according to a survey conducted by Shirely Dicke & Co., PLLC on behalf of Bensons for Babies Foundation in collaboration with Harris Poll from March 2018 to April 2018 across U.S.
Growth Factors:
- Increasing prevalence of CNS disorders such as ADHD, Alzheimer's disease, and Parkinson's disease is expected to drive the demand for CNS stimulant drugs over the forecast period.
- Rising geriatric population is also anticipated to boost the demand for these drugs as they are more susceptible to CNS disorders.
- Growing awareness about the benefits of CNS stimulant drugs is projected to propel their demand in both developed and developing countries.
- Technological advancements in drug delivery systems are likely to provide a fillip to the growth of this market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Central Nervous System (CNS) Stimulant Drugs Market Research Report
By Type
Attention-deficit Hyperactivity Disorder, Narcolepsy, Others
By Application
Hospital, Research Institutes and Research Institutions, Clinic, Other
By Companies
GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Central Nervous System (CNS) Stimulant Drugs Market Report Segments:
The global Central Nervous System (CNS) Stimulant Drugs market is segmented on the basis of:
Types
Attention-deficit Hyperactivity Disorder, Narcolepsy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institutes and Research Institutions, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline Plc
- Johnson & Johnson Services Inc.
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
 Stimulant Drugs Market Overview.svg)
Highlights of The Central Nervous System (CNS) Stimulant Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Attention-deficit Hyperactivity Disorder
- Narcolepsy
- Others
- By Application:
- Hospital
- Research Institutes and Research Institutions
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Central Nervous System (CNS) Stimulant Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Stimulant Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Central nervous system stimulant drugs are medications that increase the activity of the central nervous system. This can include increasing alertness, energy, and focus. Stimulant drugs may also be used to treat conditions such as ADHD, narcolepsy, and depression.
Some of the key players operating in the central nervous system (cns) stimulant drugs market are GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd..
The central nervous system (cns) stimulant drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Central Nervous System (CNS) Stimulant Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Central Nervous System (CNS) Stimulant Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Central Nervous System (CNS) Stimulant Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Central Nervous System (CNS) Stimulant Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Central Nervous System (CNS) Stimulant Drugs Market Size & Forecast, 2018-2028
4.5.1 Central Nervous System (CNS) Stimulant Drugs Market Size and Y-o-Y Growth
4.5.2 Central Nervous System (CNS) Stimulant Drugs Market Absolute $ Opportunity
Chapter 5 Global Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
5.2.1 Attention-deficit Hyperactivity Disorder
5.2.2 Narcolepsy
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institutes and Research Institutions
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Central Nervous System (CNS) Stimulant Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
9.6.1 Attention-deficit Hyperactivity Disorder
9.6.2 Narcolepsy
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institutes and Research Institutions
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Central Nervous System (CNS) Stimulant Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
10.6.1 Attention-deficit Hyperactivity Disorder
10.6.2 Narcolepsy
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institutes and Research Institutions
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
11.6.1 Attention-deficit Hyperactivity Disorder
11.6.2 Narcolepsy
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institutes and Research Institutions
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Central Nervous System (CNS) Stimulant Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
12.6.1 Attention-deficit Hyperactivity Disorder
12.6.2 Narcolepsy
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institutes and Research Institutions
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Central Nervous System (CNS) Stimulant Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type
13.6.1 Attention-deficit Hyperactivity Disorder
13.6.2 Narcolepsy
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institutes and Research Institutions
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Central Nervous System (CNS) Stimulant Drugs Market: Competitive Dashboard
14.2 Global Central Nervous System (CNS) Stimulant Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline Plc
14.3.2 Johnson & Johnson Services Inc.
14.3.3 Novartis AG
14.3.4 Pfizer Inc.
14.3.5 Teva Pharmaceutical Industries Ltd.
